跳转至内容
Merck
CN
  • Plasma polyunsaturated fatty acids and periodontal recovery in Taiwanese with periodontitis: a significant relationship.

Plasma polyunsaturated fatty acids and periodontal recovery in Taiwanese with periodontitis: a significant relationship.

Archives of oral biology (2014-05-27)
Sheng-Hung Wang, Hsin-Chia Hung, Chi-Cheng Tsai, Meng-Chuan Huang, Kun-Yen Ho, Yi-Min Wu, Yen-Yun Wang, Ying-Chu Lin
摘要

Plasma levels of polyunsaturated fatty acids (PUFAs) are different before and after periodontal treatment. Asians and Westerners have significantly different baseline levels of plasma PUFAs. However, no Asian study has reported the effects of nonsurgical treatment on the correlation between periodontal condition and plasma levels of PUFAs. We analyzed whether recovery from periodontitis was correlated with the elevation of plasma fatty acids 3 months after the nonsurgical intervention and with no recommended supplements. Thirty-five Taiwanese patients with periodontitis were recruited. Probing pocket depths (PPDs) and clinical attachment levels (CALs) were measured at baseline and 3 months after the nonsurgical treatment. Plasma levels of fatty acids were determined using gas chromatography. Differences and correlations between plasma fatty acid composition and periodontitis severity at baseline and 3 months after treatment were determined. Twenty-six patients completed the study. At the baseline, PPDs were negatively correlated with plasma n-3 PUFAs (r=-0.52, p<0.01), but at 3 months post intervention, periodontitis severity had declined and the weight percentages of n-3 PUFAs, DPA, and DHA were significantly (p=0.019, 0.005, and 0.037, respectively) higher. The recovery percentages of CALs were positively and significantly correlated with plasma ΔPUFAs and the percentage of Δn-3 PUFAs in ΔPUFAs (r=0.42 and 0.45, respectively; p<0.05 for both). We conclude that a higher weight percentage of n-3 PUFAs in total PUFAs was related to the recovery of CALs 3 months after the nonsurgical periodontal treatment. However, no such relationship was found for PPDs.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
二氯甲烷, suitable for HPLC, ≥99.8%, contains amylene as stabilizer
Sigma-Aldrich
二氯甲烷, contains 40-150 ppm amylene as stabilizer, ACS reagent, ≥99.5%
Sigma-Aldrich
二氯甲烷, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%, contains 50-150 ppm amylene as stabilizer
Sigma-Aldrich
二氯甲烷, anhydrous, ≥99.8%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
2,6-二--丁基-4-甲基苯酚, ≥99.0% (GC), powder
Sigma-Aldrich
二氯甲烷, puriss. p.a., ACS reagent, reag. ISO, ≥99.9% (GC)
Sigma-Aldrich
二氯甲烷, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Supelco
2,6-二叔丁基-4-甲基苯酚, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
丁羟甲苯, ≥99%, FCC, FG
Sigma-Aldrich
二氯甲烷, puriss., meets analytical specification of Ph. Eur., NF, ≥99% (GC)
Supelco
二氯甲烷, Pharmaceutical Secondary Standard; Certified Reference Material
USP
二丁基羟基甲苯, United States Pharmacopeia (USP) Reference Standard
Supelco
二氯甲烷, analytical standard
Sigma-Aldrich
2,6-二--丁基-4-甲基苯酚, purum, ≥99.0% (GC)
Sigma-Aldrich
二氯甲烷, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
二氯甲烷, suitable for HPLC, ≥99.9%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
二氯甲烷, biotech. grade, 99.9%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
2,6-二--丁基-4-甲基苯酚, tested according to Ph. Eur.
Supelco
二氯甲烷, Selectophore, ≥99.5%